KDR

(redirected from VEGFR)
Also found in: Acronyms.

KDR

A gene on chromosome 4q11-q12 that encodes a vascular endothelial growth factor receptor known as kinase insert domain receptor, which is a type-III receptor tyrosine kinase. KDR is the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting.

Molecular pathology
KDR mutations have been linked to infantile capillary haemangiomas.
Mentioned in ?
References in periodicals archive ?
Sulfatinib is an oral drug candidate that selectively inhibits the tyrosine kinase activity associated with VEGFR and FGFR.
While inhibition of VEGFR has known clinical activity in the treatment of metastatic breast cancer, this is obviously dependent on which drugs are used and their binding to specific VEGFR isoforms.
Targeted agents in development for renal cell cancer Agent Mechanism of action Manufacturer Status Everolimus mTOR inhibitor Novartis Phase III Lenalidomide Imid angiogenesis inhibitor Celgene Phase II Pazopanib VEGFR, PDGFR, and c-kit GSK Phase III tyrosine kinase inhibitor Axitinib VEGFR and PDGFR tyrosine Pfizer Phase II kinase inhibitor Lapatinib EGFR and erb-2 tyrosine GSK Phase II kinase inhibitor Vatalanib VEGFR, PDGFR, and c-kit Novartis Phase II tyrosine kinase inhibitor VEGF Trap VEGF ligand inhibitor Various Phase II VEGFR indicates vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor.
VEGFR is the major positive signal transducer for endothelial cell proliferation and differentiation.
So, we investigated the inhibition on VEGFR and the effect on apotosis of Ardipusilloside I.
Our results demonstrated that Ardipusilloside I selectively caused growth arrest and apoptosis in NCI-H460 cells and this appeared to be mediated by the regulation of Bcl-2, Bax and VEGFR.
ELISA kit for human VEGFR was purchased from R&D Systems (Minneapolis, MN, USA).
We used the Wilcoxon rank-sum test for statistical analysis of total VEGF, VEGF splice variants, and VEGFR expression in pairs of malignant and healthy tissue and Spearman rank R to test for unadjusted associations between total VEGF, VEGF splice variants, and VEGFR values and independent variables.
The expression of both VEGFRs, VEGFR-1 and VEGFR-2, was similar between paired specimens (Table 3; Fig.
4] Nonstandard abbreviations: VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; NSCLC, non-small cell lung cancer; RT-PCR, reverse transcription PCR.
The sequences of the primers and probes for VEGFRs are presented in Table 2.
Telatinib Telatinib, is a potent and selective small molecule VEGFR inhibitor ready for Phase III in gastric cancer, a leading cause of cancer-related death in China.